New hope for lung cancer patients with no PD-L1 marker

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Be≥18 to ≤ 75 years of age at enrollment, male or female. 2. Histologically or cytologically confirmed locally advanced (Stage IIIB/IIIC) that not amenable to complete surgical resection and not amenable to radical concurrent/sequential chemoradiation or metastatic (Stage IV) NSCLC (American Joint Committee on Cancer \[AJCC\] 8th edition). 3. No EGFR sensitive mutations or ALK gene translocation alterations. 4. Capable of providing fresh or archived 2 years' tissue samples collected at post-diagnosis or non-radiation sites at diagnosis for central laboratory PD-L1 testing with TPS \< 1% . 5. Have a life expectancy of at least 3 months. 6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 7. No prior systemic therapy for advanced or metastatic NSCLC was received. Exclusion Criteria: 1. Previous treatment with immune checkpoint inhibitors (PD-1/PD-L1 drugs or drugs acting on another T cell receptor (e.g., CTLA-4 etc.), as well as immune checkpoint agonistic antibodies (e.g., anti ICOS , CD40 , CD137 , GITR , OX40 antibodies, etc.), and immune cell therapy. 2. Patients who have received systemic corticosteroids or other immunosuppressive drugs within 2 weeks prior to the first dose. 3. Presence or history of any active autoimmune disease, including, but not limited to: autoimmune hepatitis, interstitial pneumonia, pulmonary fibrosis, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism. 4. Pulmonary radiation therapy \> 30 Gy within 6 months prior to first dose; 5. Palliative radiotherapy completed 7 days prior to first dose. 6. Known or symptomatic active central nervous system (CNS) metastases or carcinomatous meningitis during screening. 7. Clinically significant cardiovascular or cerebrovascular disease \-